<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168024</url>
  </required_header>
  <id_info>
    <org_study_id>TP-6142</org_study_id>
    <nct_id>NCT01168024</nct_id>
  </id_info>
  <brief_title>Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)</brief_title>
  <official_title>PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osprey Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osprey Medical, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey
      Medical CINCOR™ Contrast Removal System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CINCOR™ Catheter System to retrieve contrast media from the coronary sinus following
      injection during percutaneous coronary interventions.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed by sponsor prior to completing enrollment goal.
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Contrast Induced Nephropathy (CIN) in Subjects.</measure>
    <time_frame>Through 72 hours post-procedure</time_frame>
    <description>CIN is defined as a post-procedure relative serum creatinine increase ≥ 25% or an absolute serum creatinine increase of ≥ 0.5 mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating Bleeding/Transfusion Events.</measure>
    <time_frame>Through 30 days post-procedure</time_frame>
    <description>Bleeding/transfusion events evaluated:
Blood loss requiring transfusion of ≥ 2 units
Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
TIMI Minor Bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating Local Events.</measure>
    <time_frame>Through 30 days post-procedure.</time_frame>
    <description>Events evaluated include:
Coronary sinus perforation, dissection, or occlusion that requires treatment or results in MI or death
Pericardial effusions (including pericardial tamponade) requiring treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Kidney Function Between the Randomized Groups.</measure>
    <time_frame>Up to 96 hours post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Radiographic Contrast Agent Nephropathy</condition>
  <arm_group>
    <arm_group_label>CINCOR™ System Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the CINCOR™ System and CCS-1 device during the pericutanous coronary intervention (PCI) procedure plus Standard of Care peri-procedural hydration for the prevention of contrast induced nephropathy (CIN).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group will receive a peri and post-procedural hydration rate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CINCOR™ System and contrast conservation unit (CCS-1)</intervention_name>
    <description>Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media</description>
    <arm_group_label>CINCOR™ System Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care plus peri-procedural hydration</intervention_name>
    <description>The control group will receive a peri and post-procedural hydration rate.</description>
    <arm_group_label>CINCOR™ System Treatment</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is at least 18 years of age.

          2. The subject is a candidate for a therapeutic coronary PCI procedure of the left
             coronary artery and/or its branches or a combination procedure including left coronary
             artery/branches AND right coronary artery that is expected to utilize at least 50 mL
             of iodinated contrast media.

          3. The subject has baseline eGFR between 20 and 30 mL/min/1.73 m2 inclusive (as
             determined by the MDRD equation (Levey 1993)); or patient has eGFR above 30 but less
             than or equal to 60 with at least two of the following: stage III/IV NYHA congestive
             heart failure, diabetes mellitus, hypertension, age of at least 75 years.

          4. The subject (or subject's legal representative) is willing and able to provide
             appropriate informed consent.

          5. The subject is willing and able to comply with the requirements of the study protocol,
             including the predefined follow-up evaluations.

        Exclusion Criteria:

          1. The subject has unstable renal function (acute renal failure or change in serum
             creatinine of &gt; 0.5mg/dL or &gt; 25% within 7 days of the procedure not attributed to
             hydration therapy).

          2. The subject requires dialysis.

          3. The subject has received contrast media within 7 days of the procedure.

          4. The subject will receive &gt; 10 ml of iodinated contrast media in any location other
             than the coronary arteries (e.g. ventriculography, aortography, renal angiography)
             during the procedure or within a period of 30 days after the procedure.

          5. The subject requires one or more of the following nephrotoxic agents: Aminoglycoside
             antibiotics, Sulfonamides, Amphotericin B, Levofloxacin, Ciprofloxacin, Rifampin,
             Tetracycline, Intravenous Acyclovir, Pentamidine, Penicillin and Cephalosporins,
             Cisplatin, Methotrexate, Mitomycin, Cyclosporine, Tacrolimus.

          6. The subject has hemoglobin (Hb) &lt; 9.5 g/dL within one (1) week of the procedure.

          7. The subject is hemodynamically unstable or requires hemodynamic support including
             intra-venous inotropes, vasopressors, or any type of ventricular assist devices
             (including intra-aortic balloon pumps, the Impella cardiac assist device, the
             TandemHeart VAD, and surgically implanted ventricular assist devices).

          8. The subject has had acute myocardial infarction within last 24 hours (as defined in
             the &quot;Universal Definition of Myocardial Infarction (Thygesen 2007) or has biomarkers
             of cardiac injury that have not stabilized. (Patients with MI within 96 hours of index
             procedure must demonstrate falling biomarkers of cardiac injury).

          9. The subject has any of the following procedural contra-indications

               1. has a left heart pacing lead or other implant indwelling in the coronary sinus or
                  has had an artificial valve or pacemaker lead implanted in the right heart within
                  8 weeks of the planned procedure

               2. has a known bleeding diathesis (e.g. thrombocytopenia [&lt;100,000 cells/mm3],
                  heparin-induced thrombocytopenia, hemophilia, or von Willebrand disease, any
                  history of intracranial bleeding, or gastrointestinal or gross genitourinary
                  bleeding)

               3. The subject is currently on intravenous anti-coagulation that cannot be
                  discontinued prior to the procedure

               4. The subject has a known hypersensitivity to both heparin and bivalirudin or
                  aspirin or all thienopyridine agents or iodinated contrast that cannot be
                  adequately pre-medicated

               5. The subject has an active systemic infection

               6. The subject refuses to accept blood products (e.g. Jehovah's Witness)

         10. The subject is known to be or suspected to be pregnant, or is lactating (all women of
             child-bearing potential must have a negative pregnancy test within 72 hours before
             participating in this protocol).

         11. The subject is currently participating in another investigational device or drug study
             that has not reached its primary endpoint.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Care Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart and Vascular Institute of Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elyria Memorial Hospital Medical Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation for Cardiovascular Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Heart Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennova Healthcare - Turkey Creek Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital of Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas, PA</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Center Leipzig Ltd.</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <results_first_submitted>June 27, 2016</results_first_submitted>
  <results_first_submitted_qc>October 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2016</results_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>Iodinated Contrast Agent Retrieval</keyword>
  <keyword>Coronary Sinus Cannulation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CINCOR™ System and CCS-1</title>
          <description>Use of the CINCOR™ System and CCS-1 device during the PCI procedure plus Standard of Care peri-procedural hydration for the prevention of CIN.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care Plus Peri-procedural Hydration</title>
          <description>Peri-procedural hydration utilized prior to standard of care PCI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">13 tx/3 controls. Roll-ins occurred for product training, several more treatment cases than control.</participants>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrollment allowed for both non-randomized roll-in and randomized subjects. Up to three roll-in subjects (maximum of 150 in the trial) were allowed per center to address learning curve issues associated with the coronary sinus cannulation technique and device use.</population>
      <group_list>
        <group group_id="B1">
          <title>CINCOR™ System Treatment</title>
          <description>Use of the CINCOR™ System and CCS-1 device during the PCI procedure plus Standard of Care peri-procedural hydration for the prevention of CIN.
CINCOR™ System and CCS-1: Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
Peri-procedural hydration: The control group will receive a peri and post-procedural hydration rate.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Peri-procedural hydration with isotonic saline or sodium bicarbonate for at least 2 hours prior to the procedure and 6-12 hours post-procedure.
Peri-procedural hydration: The control group will receive a peri and post-procedural hydration rate.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="11.5"/>
                    <measurement group_id="B2" value="82" spread="13.8"/>
                    <measurement group_id="B3" value="71" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Contrast Induced Nephropathy (CIN) in Subjects.</title>
        <description>CIN is defined as a post-procedure relative serum creatinine increase ≥ 25% or an absolute serum creatinine increase of ≥ 0.5 mg/dL).</description>
        <time_frame>Through 72 hours post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Roll In and Randomized)</title>
            <description>CINCOR, CCS-1 and Peri-procedure hydration</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Peri-procedure hydration</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Contrast Induced Nephropathy (CIN) in Subjects.</title>
          <description>CIN is defined as a post-procedure relative serum creatinine increase ≥ 25% or an absolute serum creatinine increase of ≥ 0.5 mg/dL).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluating Bleeding/Transfusion Events.</title>
        <description>Bleeding/transfusion events evaluated:
Blood loss requiring transfusion of ≥ 2 units
Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
TIMI Minor Bleeding</description>
        <time_frame>Through 30 days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Roll In and Randomized)</title>
            <description>CINCOR, CCS-1 and Peri-procedure hydration</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Peri-procedure hydration</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluating Bleeding/Transfusion Events.</title>
          <description>Bleeding/transfusion events evaluated:
Blood loss requiring transfusion of ≥ 2 units
Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
TIMI Minor Bleeding</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluating Local Events.</title>
        <description>Events evaluated include:
Coronary sinus perforation, dissection, or occlusion that requires treatment or results in MI or death
Pericardial effusions (including pericardial tamponade) requiring treatment</description>
        <time_frame>Through 30 days post-procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Roll In and Randomized)</title>
            <description>CINCOR, CCS-1 and Peri-procedure hydration</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Peri-procedure hydration</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluating Local Events.</title>
          <description>Events evaluated include:
Coronary sinus perforation, dissection, or occlusion that requires treatment or results in MI or death
Pericardial effusions (including pericardial tamponade) requiring treatment</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Kidney Function Between the Randomized Groups.</title>
        <time_frame>Up to 96 hours post-procedure</time_frame>
        <population>Change in eGFR was available for 2 treatment and 1 control subject. 1 out of range eGFR value for a subject (0.1) was not used as this value is not clinically feasible.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Roll In and Randomized)</title>
            <description>CINCOR, CCS-1 and Peri-procedure hydration</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Peri-procedure hydration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Kidney Function Between the Randomized Groups.</title>
          <population>Change in eGFR was available for 2 treatment and 1 control subject. 1 out of range eGFR value for a subject (0.1) was not used as this value is not clinically feasible.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.33" spread="1.10"/>
                    <measurement group_id="O2" value="-6.95" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported through the 30 day follow up period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Roll In and Randomized)</title>
          <description>CINCOR, CCS-1 and Peri-procedure hydration</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Peri-procedure hydration</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>STEMI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Troponin Elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Minor Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Of Clinial Affairs</name_or_title>
      <organization>Osprey Medical</organization>
      <phone>952-955-8230</phone>
      <email>mshepard@ospreymed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

